Guyasuta Investment Advisors Inc. Has $314,000 Stock Position in Danaher Co. (NYSE:DHR)

Guyasuta Investment Advisors Inc. lifted its stake in Danaher Co. (NYSE:DHR) by 36.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,359 shares of the conglomerate’s stock after acquiring an additional 363 shares during the period. Guyasuta Investment Advisors Inc.’s holdings in Danaher were worth $314,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of DHR. Nicholas Hoffman & Company LLC. increased its stake in shares of Danaher by 2.3% in the 4th quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock valued at $439,000 after acquiring an additional 43 shares during the last quarter. Drive Wealth Management LLC increased its stake in shares of Danaher by 3.1% in the 4th quarter. Drive Wealth Management LLC now owns 1,485 shares of the conglomerate’s stock valued at $344,000 after acquiring an additional 44 shares during the last quarter. Trust Investment Advisors increased its stake in shares of Danaher by 1.8% in the 4th quarter. Trust Investment Advisors now owns 2,811 shares of the conglomerate’s stock valued at $650,000 after acquiring an additional 49 shares during the last quarter. Austin Private Wealth LLC increased its stake in shares of Danaher by 3.4% in the 3rd quarter. Austin Private Wealth LLC now owns 1,566 shares of the conglomerate’s stock valued at $389,000 after acquiring an additional 51 shares during the last quarter. Finally, JGP Wealth Management LLC increased its stake in shares of Danaher by 2.1% in the 4th quarter. JGP Wealth Management LLC now owns 2,564 shares of the conglomerate’s stock valued at $593,000 after acquiring an additional 53 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Up 0.1 %

Shares of Danaher stock opened at $246.82 on Tuesday. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $259.00. The stock has a market cap of $182.82 billion, a P/E ratio of 41.83, a P/E/G ratio of 3.80 and a beta of 0.83. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The business’s 50 day moving average is $248.80 and its 200-day moving average is $231.53.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter in the prior year, the business posted $2.36 EPS. The business’s revenue was down 2.6% compared to the same quarter last year. Equities research analysts predict that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 26th. Stockholders of record on Thursday, March 28th were paid a dividend of $0.27 per share. The ex-dividend date was Wednesday, March 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio is currently 18.31%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on DHR. Citigroup boosted their price objective on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Bank of America boosted their price objective on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research report on Wednesday, April 24th. KeyCorp boosted their price objective on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Robert W. Baird boosted their price objective on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Finally, Raymond James boosted their price objective on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Six equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average target price of $269.64.

Insider Transactions at Danaher

In other news, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the sale, the senior vice president now owns 4,244 shares in the company, valued at approximately $1,029,891.48. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total value of $636,280.74. Following the sale, the senior vice president now owns 4,244 shares in the company, valued at approximately $1,029,891.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Walter G. Lohr sold 3,289 shares of the stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $251.15, for a total value of $826,032.35. Following the completion of the sale, the director now owns 14,129 shares in the company, valued at approximately $3,548,498.35. The disclosure for this sale can be found here. Insiders have sold a total of 106,565 shares of company stock worth $26,641,364 in the last 90 days. Corporate insiders own 10.90% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.